日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Identification of novel regulators of LINE-1 expression via CRISPR/Cas9 screening.

利用 CRISPR/Cas9 筛选鉴定 LINE-1 表达的新调控因子。

Oksuz Ozgur, Chu Chong, Arisdakessian Cedric, Diao Liyang, Zaller Dennis, Long Kimberly K, Keilhack Heike, Knutson Sarah

Selective Pharmaceutical Inhibition of PARP14 Mitigates Allergen-Induced IgE and Mucus Overproduction in a Mouse Model of Pulmonary Allergic Response

选择性药物抑制 PARP14 可减轻小鼠肺部过敏反应模型中过敏原诱导的 IgE 和粘液过量产生

Alex M Eddie, Kevin W Chen, Laurie B Schenkel, Kerren K Swinger, Jennifer R Molina, Kaiko Kunii, Ariel L Raybuck, Heike Keilhack, Katherine N Gibson-Corley, Mario Niepel, R Stokes Peebles, Mark R Boothby, Sung Hoon Cho

Novel synthetic pathway for the production of phosgene

一种新型的光气合成途径

Voßnacker, Patrick; Wüst, Alisa; Keilhack, Thomas; Müller, Carsten; Steinhauer, Simon; Beckers, Helmut; Yogendra, Sivathmeehan; Schiesser, Yuliya; Weber, Rainer; Reimann, Marc; Müller, Robert; Kaupp, Martin; Riedel, Sebastian

Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models

通过抑制 EZH2 选择性杀死 SMARCA2 和 SMARCA4 缺陷型卵巢小细胞癌、高钙血症型细胞:体外和体内临床前模型

Elayne Chan-Penebre, Kelli Armstrong, Allison Drew, Alexandra R Grassian, Igor Feldman, Sarah K Knutson, Kristy Kuplast-Barr, Maria Roche, John Campbell, Peter Ho, Robert A Copeland, Richard Chesworth, Jesse J Smith, Heike Keilhack, Scott A Ribich

EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL

他泽司他抑制 EZH2 导致 DLBCL 对 B 细胞活化信号的依赖性改变

Dorothy Brach, Danielle Johnston-Blackwell, Allison Drew, Trupti Lingaraj, Vinny Motwani, Natalie M Warholic, Igor Feldman, Christopher Plescia, Jesse J Smith, Robert A Copeland, Heike Keilhack, Elayne Chan-Penebre, Sarah K Knutson, Scott A Ribich, Alejandra Raimondi, Michael J Thomenius

Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program

儿科临床前测试计划对新型 EZH2 抑制剂他泽司他 (EPZ-6438) 进行初步测试(第 1 阶段)

Raushan T Kurmasheva, Melissa Sammons, Edward Favours, Jianwrong Wu, Dias Kurmashev, Katherine Cosmopoulos, Heike Keilhack, Christine R Klaus, Peter J Houghton, Malcolm A Smith

Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma

EZH2 抑制在人类滑膜肉瘤模型中诱导抗肿瘤活性的临床前证据

Satoshi Kawano, Alexandra R Grassian, Masumi Tsuda, Sarah K Knutson, Natalie M Warholic, Galina Kuznetsov, Shanqin Xu, Yonghong Xiao, Roy M Pollock, Jesse S Smith, Kevin K Kuntz, Scott Ribich, Yukinori Minoshima, Junji Matsui, Robert A Copeland, Shinya Tanaka, Heike Keilhack

EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity

EPZ011989,一种高效、口服有效的EZH2抑制剂,具有显著的体内活性。

Campbell, John E; Kuntz, Kevin W; Knutson, Sarah K; Warholic, Natalie M; Keilhack, Heike; Wigle, Tim J; Raimondi, Alejandra; Klaus, Christine R; Rioux, Nathalie; Yokoi, Akira; Kawano, Satoshi; Minoshima, Yukinori; Choi, Hyeong-Wook; Porter Scott, Margaret; Waters, Nigel J; Smith, Jesse J; Chesworth, Richard; Moyer, Mikel P; Copeland, Robert A

A Medium-Throughput Single Cell CRISPR-Cas9 Assay to Assess Gene Essentiality

中通量单细胞 CRISPR-Cas9 检测以评估基因必需性

A R Grassian #, T M E Scales #, S K Knutson, K W Kuntz, N J McCarthy, C E Lowe, J D Moore, R A Copeland, H Keilhack, J J Smith, J A Wickenden, S Ribich

Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas

EZH2 抑制剂和糖皮质激素受体激动剂在生发中心非霍奇金淋巴瘤模型中的协同抗肿瘤活性

Sarah K Knutson, Natalie M Warholic, L Danielle Johnston, Christine R Klaus, Tim J Wigle, Dorothy Iwanowicz, Bruce A Littlefield, Margaret Porter-Scott, Jesse J Smith, Mikel P Moyer, Robert A Copeland, Roy M Pollock, Kevin W Kuntz, Alejandra Raimondi, Heike Keilhack